Homestead Advisers Corp Sells 223,100 Shares of Boston Scientific Corporation $BSX

Homestead Advisers Corp trimmed its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 22.7% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 759,426 shares of the medical equipment provider’s stock after selling 223,100 shares during the period. Boston Scientific comprises approximately 1.9% of Homestead Advisers Corp’s investment portfolio, making the stock its 21st largest holding. Homestead Advisers Corp’s holdings in Boston Scientific were worth $81,570,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. 1248 Management LLC purchased a new stake in Boston Scientific in the first quarter worth $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific during the 1st quarter worth $27,000. Sound Income Strategies LLC grew its stake in shares of Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares during the period. Princeton Global Asset Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $32,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Boston Scientific during the second quarter valued at about $37,000. Institutional investors own 89.07% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently commented on BSX shares. Truist Financial upped their price target on shares of Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Royal Bank Of Canada reissued an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a report on Monday, September 29th. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a research report on Wednesday, October 22nd. UBS Group lifted their price target on Boston Scientific from $135.00 to $140.00 and gave the company a “buy” rating in a research report on Thursday, October 23rd. Finally, Erste Group Bank cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $123.77.

Insider Buying and Selling at Boston Scientific

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ellen M. Zane sold 2,901 shares of the firm’s stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $102.24, for a total value of $296,598.24. Following the transaction, the director owned 24,134 shares in the company, valued at approximately $2,467,460.16. The trade was a 10.73% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 162,891 shares of company stock valued at $16,475,387 over the last three months. 0.50% of the stock is currently owned by insiders.

Boston Scientific Trading Up 0.2%

Shares of BSX stock opened at $98.79 on Wednesday. The business has a 50-day moving average price of $100.48 and a two-hundred day moving average price of $102.45. Boston Scientific Corporation has a 12-month low of $84.13 and a 12-month high of $109.50. The company has a quick ratio of 0.82, a current ratio of 1.37 and a debt-to-equity ratio of 0.49. The firm has a market cap of $146.38 billion, a P/E ratio of 52.83, a price-to-earnings-growth ratio of 2.02 and a beta of 0.61.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. During the same period in the previous year, the business posted $0.63 EPS. The business’s quarterly revenue was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts anticipate that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.